



SPECIAL SEMINAR SERIES

NCCR CHEMICAL
BIOLOGY

DARIO NERI

Armed antibodies and targeted cytotoxics for the treatment of cancer and of rheumatoid arthritis: from the bench to the clinic

1 DECEMBER 2015 - 16:15 // EPFL
SV 1717 A

Dario Neri is a Professor at the ETH Zürich in the department of Chemistry and Applied Biosciences, and a co-founder of Philogen, a Swiss-Italian biotech company.



The research of the group Neri focuses on the engineering of therapeutic antibodies for the treatment of cancer and of chronic inflammatory conditions. Other research activities include the development of DNA-encoded chemical libraries and of small molecule-drug conjugates. Furthermore, the group uses mass spectrometry methodologies for the discovery of vascular markers of disease and for HLA peptidome analysis.

